HOME >> MEDICINE >> NEWS
Major overhaul needed in end-of life care for patients with dementia

Three University of Chicago geriatricians are calling for creative and wide-reaching solutions to the problem of sub-optimal end-of-life care for patients with dementia. An estimated 500,000 people die every year in the United States suffering from Alzheimer's or related diseases and many of them receive inadequate pain control, are subjected to ineffective and invasive therapies such as tube feedings, and do not receive the benefits of hospice care.

"The nature of the illness is the root cause of the problem," said Greg Sachs, M.D., professor of medicine, section chief of geriatrics at the University of Chicago and first author of the study. "Our health care system is oriented toward treatment of acute illness but dementia produces a long, slow, unpredictable decline."

Their study is one of four in the October, 2004, issue of the Journal of General Internal Medicine that focus on the expanding role of primary care physicians in the care of patients with chronic and ultimately terminal illness a growing, difficult problem for physicians and for society.

Death used to come quickly, but now it "fades in slowly -- over years or even decades," notes Christopher Callahan, M.D., of the Indiana University Center for Aging Research, in an editorial that ties together the four papers. The pace of death, he adds, "has slowed so suddenly that we seem to have lost our ability to recognize it." As a result, "we find ourselves poorly trained, our systems poorly designed, and our patients and communities poorly equipped."

"All the barriers and problems seem to converge," he adds, in end-of-life care for patients with dementia.

The Chicago geriatricians list the barriers to optimal care for such patients and suggest ways to get past them.

The first hurdle is the unwillingness of physicians and families to think of dementia as a terminal illness. Patients with dementia decline slowly, with long periods of st
'"/>

Contact: John Easton
John.Easton@uchospitals.edu
773 702 6241
University of Chicago Medical Center
14-Oct-2004


Page: 1 2 3

Related medicine news :

1. Major review of subway systems suggests potential for significant health and safety hazards
2. Major step forwards for vaccine against cervical cancer
3. Majority of cigarettes in the US smoked by nicotine-dependent or psychiatrically ill persons
4. Major overhaul needed in end-of life care for patients with dementia
5. Major radiology journal offers unrestricted access to recently archived articles
6. Major study: Bioartificial liver reduces mortality by 44 percent in acute liver-failure patients
7. Majority of authors retract 1998 Lancet paper-Lancet editor points to implications
8. Major agreement reached at heart health conference
9. Major risk factors identified for sudden infant death syndrome
10. Major cause of painful gastroenteritis under study at MCG
11. Major advance in chemotherapy in breast cancer

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Major overhaul needed end life care for patients with dementia

(Date:10/22/2014)... HealthDay Reporter TUESDAY, Oct. 21, 2014 (HealthDay ... (IVF) -- the incubation of embryos in a laboratory dish ... vagina, new research suggests. Scientists from the United States ... sharply cut costs for pricey IVF procedures among certain women. ... who don,t live near big-city assisted reproduction centers, the researchers ...
(Date:10/22/2014)... Dennis Thompson HealthDay Reporter ... officials on Monday officially tightened guidelines for health workers treating ... exposure and use of a respirator at all times. ... issue the tougher rules after two Dallas nurses contracted Ebola ... United States, Liberian national Thomas Eric Duncan. Nina Pham is ...
(Date:10/20/2014)... Dallas, Texas (PRWEB) October 20, 2014 ... is the must-have source of thousands of facts, figures ... 72 countries and 68 medical sector forecast categories the ... you with global, regional and national views on the ... future outlook. , The report gives you data for ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Allegheny General ... procedure that enables physicians to repair a damaged mitral ... MitraClip system, developed by Abbott Vascular ... a progressive and life-threatening condition in which the heart’s ... to flow backward from the heart’s left ventricle into ...
(Date:10/20/2014)... ASCNYC (ascnyc.org) is a New ... Yorkers living with HIV/AIDS and other chronic conditions ... and self-sufficiency. Each year, ASCNYC spotlights selected “Positive ... their tireless efforts. , Savills Studley ... been selected as this year’s honoree for sharing ...
Breaking Medicine News(10 mins):Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3
(Date:10/22/2014)...   Surefire Medical , Inc., the developer of ... targeted delivery of embolization agents in minimally invasive direct-to-tumor ... John R. Daniels , MD of the University of ... Steven C. Katz , MD of the Roger ... Board (SAB).    "The role of the ...
(Date:10/22/2014)... and AUSTIN, Texas ... and PureMHC LLC today announced they have entered ... novel antibody-based immunotherapies designed to target cancers. ... phosphorylated peptides displayed on the surfaces of tumor ... tumor targets (PTTs), derived from proteins that play ...
(Date:10/22/2014)... , Oct. 22, 2014  Regulus ... a biopharmaceutical company leading the discovery and ... announced that it has demonstrated human proof-of-concept ... clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated ... of hepatitis C virus infection ("HCV").  Interim ...
Breaking Medicine Technology:Surefire Medical's Scientific Advisory Board Expands, Broadens Clinical Trial Expertise 2Biotech Companies To Co-Discover And Co-Develop Antibodies Targeting Novel Phosphopeptide Tumor Targets 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8
Cached News: